Featured Publication Advancing Shared Goals Click here to read the full reportResearch Papers Savings from the introduction of BPaL and BPaLM regimens at the country level Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the Philippines Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trialFor the PressPress Contact:Jess Wiggsp | +1 646 616 8613e | jessica.wiggs@tballiance.org View the 2023 Annual Report
